中文

Global search

Find data and evidence

Type at least 2 characters. Use arrow keys to review and Enter to open.

Peer reviewedHistorical baselineMalaria

First results of phase 3 trial of RTS,S/AS01 malaria vaccine in African children.

The New England journal of medicine·

RTS,S Clinical Trials Partnership, Agnandji ST, Lell B, Soulanoudjingar SS, Fernandes JF, Abossolo BP, Conzelmann C, Methogo BG

DOI
10.1056/nejmoa1102287
PMID
22007715
PMCID
—
OpenAlex
—
Study type
Randomised controlled trial
Publisher
Publisher unavailable
Article type
journal-article
Integrity
current

Why this research matters now

A phase 3 malaria vaccine milestone that helps connect current malaria surveillance with prevention evidence.

01

Structured evidence summary

Research question

What early phase 3 efficacy and safety findings were observed for RTS,S/AS01 in African children?

Study design

Phase 3 vaccine trial.

Population and setting

African children enrolled in a multicountry trial network.

Main findings

This field has not yet received a quality-gated evidence summary. Consult the original article.

Public-health relevance

Anchors malaria vaccine evidence for interpreting prevention-oriented literature.

Important limitations

Limitations could not be fully assessed from the available metadata.

GIDS interpretation

Use as a historical vaccine milestone, not as the full current evidence base.

02

Related GIDS surveillance

MalariaView available GIDS surveillance→

Literature context does not validate, explain, or change a surveillance signal. Exact and contextual relationships are shown separately.

03

Evidence relationships

This article has 8 auditable classifier relationships to diseases, places, topics, and study design.

about diseaseaddresses topicaddresses topicaddresses topicevaluates interventionevaluates interventionstudied population settinguses study design
04

Ranked deterministically by shared disease, geography, topic, study design, and publication proximity. This is a discovery aid, not a quality judgment.

  1. A Single Dose of the DENV-1 Candidate Vaccine rDEN1Δ30 Is Strongly Immunogenic and Induces Resistance to a Second Dose in a Randomized TrialPLoS Neglected Tropical Diseases · Randomised controlled trial

    Shared disease: Malaria · Shared topic: Treatment, Vaccination, Vaccine effectiveness · Same study type: Randomised controlled trial

  2. Duration and association with protection of NANP-repeat-specific and C-terminus-specific anti-circumsporozoite protein IgG responses following RTS,S/AS01E vaccination: an observational ancillary immunological study of a phase 3 clinical trialThe Lancet Infectious Diseases · Randomised controlled trial

    Shared disease: Malaria · Shared topic: Treatment, Vaccination, Vaccine effectiveness · Same study type: Randomised controlled trial

  3. Benefits and risks of the Sanofi-Pasteur dengue vaccine: Modeling optimal deploymentScience · Journal article

    Shared disease: Malaria · Shared topic: Treatment, Vaccination, Vaccine effectiveness

  4. Antibody fine specificity correlates with protection from malaria for the RTS,S vaccine in young African children: A post hoc analysis of a phase IIb randomised controlled trialPLOS Medicine · Randomised controlled trial

    Shared disease: Malaria · Shared topic: Treatment, Vaccination · Same study type: Randomised controlled trial

  5. Country specific predictions of the cost-effectiveness of malaria vaccine RTS,S/AS01 in endemic AfricaVaccine · Randomised controlled trial

    Shared disease: Malaria · Shared topic: Vaccination, Vaccine effectiveness · Same study type: Randomised controlled trial

  6. Public health impact and cost-effectiveness of the RTS,S/AS01 malaria vaccine: a systematic comparison of predictions from four mathematical modelsThe Lancet · Randomised controlled trial

    Shared disease: Malaria · Shared topic: Vaccination, Vaccine effectiveness · Same study type: Randomised controlled trial